Trial Profile

The Clinical Response Evaluation of the Medtronic Endeavor CR ABT-578 Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zotarolimus (Primary)
Indications Coronary artery disease; Coronary artery restenosis
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms RESOLUTE-First in Human

Most Recent Events

19 Oct 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
23 Sep 2010 Four-year results were presented at the 2010 Transcatheter Cardiovascular Therapeutics (TCT) conference, according to a Medtronic media release.
21 Sep 2010 3-year long-term results were presented at the 22nd Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com